Limb-salvage surgery (LSS) is the cornerstone of modern osteosarcoma management, yet outcomes appear to differ substantially between pediatric and adult patients. Variability in tumor biology, chemotherapy tolerance, treatment intensity, and reconstructive durability may contribute to age-related disparities; however, comparative evidence has not been previously synthesized. This study aimed to systematically evaluate oncologic, functional, and prognostic differences in limb-salvage outcomes between pediatric and adult patients with osteosarcoma. A Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-guided systematic review was performed across major databases. Studies were eligible if they reported limb-salvage outcomes separately for pediatric and adult patients. Data extraction encompassed survival, recurrence, functional scores, chemotherapy response, and prognostic factors. Risk of bias was assessed using the Newcastle-Ottawa Scale. Seven studies met the inclusion criteria, representing over 12,000 patients from cooperative trials, national registries, and institutional cohorts. Pediatric patients consistently demonstrated superior oncologic outcomes, with higher five-year overall survival (55%-73% vs. 41%-69%) and lower distant recurrence rates compared with adults. Local recurrence remained low but was slightly more frequent in adults. Functional outcomes favored pediatric groups, who achieved higher MSTS scores and lower revision rates. Histologic response to chemotherapy ≥90% was substantially more common in children, reflecting stronger systemic treatment tolerance. Predictors of poor outcome, such as axial site, metastatic disease, comorbidities, and poor necrosis, were disproportionately represented in adult cohorts. Risk of bias was low to moderate for most studies, with consistent age-related patterns across all evidence sources. Age significantly influences outcomes following LSS for osteosarcoma. Pediatric patients show superior survival, lower recurrence, improved function, and more favorable prognostic indicators compared with adults, even within similar surgical pathways. Biological differences, treatment intensity, and systemic therapy responsiveness likely contribute to these disparities. Future research should focus on optimizing chemotherapy strategies and reconstructive approaches for adults and on identifying biologic drivers that underlie these age-dependent patterns.
osteosarcomalimb salvagechildren versus adultsage disparities
Cholangiocarcinoma (CCA) is a hepatic malignancy that has a rapidly increasing incidence. CCA is anatomically classified into intrahepatic (iCCA) and extrahepatic (eCCA), which is further divided into perihilar (pCCA) and distal (dCCA) subtypes, with higher incidence rates in Asia. Despite its rarity, CCA has a low 5-year survival rate and remains the leading cause of primary liver tumor-related death over the past 10-20 years. The systemic therapy section discusses gemcitabine-based regimens as primary treatments, along with oxaliplatin-based options. Second-line therapy is limited but may include short-term infusional fluorouracil (FU) plus leucovorin (LV) and oxaliplatin. The adjuvant therapy section discusses approaches to improve overall survival (OS) post-surgery. However, only a minority of CCA patients qualify for surgical resection. In comparison to adjuvant therapies, neoadjuvant therapy for unresectable cases shows promise. Gemcitabine and cisplatin indicate potential benefits for patients awaiting liver transplantation. The addition of immunotherapies to chemotherapy in combination is discussed. Nivolumab and innovative approaches like CAR-T cells, TRBAs, and oncolytic viruses are explored. We aim in this review to provide a comprehensive report on the systemic and locoregional therapies for CCA.
INTRODUCTION: Atopic dermatitis (AD) is a chronic inflammatory skin disease that significantly impacts both pediatrics and adults. Despite the availability and proven efficacy of systemic medications, there remains a critical issue of non-adherence among patients. This study aimed to assess adherence to systemic therapy among Saudi adult patients with AD. METHODS: The study employed a cross-sectional study with an online questionnaire that was distributed among a convenience sample of 1,154 adult patients with AD in Saudi Arabia. In addition to descriptive statistical analysis, Pearson's correlation and chi-squared tests were used to determine the correlations between adherence to systemic therapy for AD and its predictable factors. RESULTS: AD was diagnosed over five years in 61.3% of the participants. The vast majority of those diagnosed with AD (73%) were prescribed systemic medications, with a moderate level of adherence to this therapy. While adherence to systemic therapy significantly correlated with improved quality of life, factors including forgetfulness, side effect concerns, patient's belief in medication importance, disease severity, and medication complexity impacted adherence to this mode of therapy. Factors including patient's belief in medication importance, disease severity, and medication complexity impacted adherence. CONCLUSION: The findings of this study highlight the need for multifaceted interventions to improve adherence to systemic therapy for AD. Addressing patient concerns about the use of systemic therapy for AD and reinforcing the importance of medication use for long-term disease management and quality-of-life improvement is recommended to explore the barriers to adherence and enhance compliance to systemic therapy in this population.